50637-27-9

Upstream product

• 50637-26-8 methyl 3-(benzyloxy)-5-methoxybenzoate 
• 19520-75-3 3-hydroxy-5-methoxybenzoic acid 
• 100-44-7 benzyl chloride 
• 54915-31-0 methyl 3-(benzyloxy)-5-hydroxybenzoate 
• 100-39-0 benzyl bromide 
• 99-10-5 3,5-Dihydroxybenzoic acid 
• 185342-16-9 (S)-4-Benzyl-3-[2-(3-benzyloxy-5-methoxy-phenyl)-acetyl]-oxazolidin-2-one 
• 19520-74-2 3-hydroxy-5-methoxy-benzoic acid methyl ester 
• 2150-44-9 1-carbomethoxy-3,5-dihydroxybenzene 
• 185342-01-2 (S)-3-[(S)-2-Azido-2-(3-benzyloxy-5-methoxy-phenyl)-acetyl]-4-benzyl-oxazolidin-2-one 

Downstream Products

• 50637-26-8 methyl 3-(benzyloxy)-5-methoxybenzoate 
• 535969-54-1 1-(3-benzyloxy-5-methoxy-phenyl)-7-methoxy-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid 
• 535969-56-3 1-(3-hydroxy-5-methoxy-phenyl)-7-methoxy-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid (3,5-difluoro-phenyl)-ethyl-amide 
• 535969-55-2 1-(3-benzyloxy-5-methoxy-phenyl)-7-methoxy-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid (3,5-difluoro-phenyl)-ethyl-amide 
• 535969-58-5 1-[3-(4-chloromethyl-benzyloxy)-5-methoxy-phenyl]-7-methoxy-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid (3,5-difluoro-phenyl)-ethyl-amide 
• 535969-88-1 1-[3-(7-bromo-heptyloxy)-5-methoxy-phenyl]-7-methoxy-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid (3,5-difluoro-phenyl)-ethyl-amide 
• 535969-62-1 1-[3-(6-iodo-hexyloxy)-5-methoxy-phenyl]-7-methoxy-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid (3,5-difluoro-phenyl)-ethyl-amide 
• 535972-41-9 1-[3-(8-bromo-octyloxy)-5-methoxy-phenyl]-7-methoxy-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid (3,5-difluoro-phenyl)-ethyl-amide 
• 1355235-78-7 N-(6-acetylbenzo[d][1,3]dioxol-5-yl)-3'-(benzoxy)-5'-methoxy-benzamide 
• 1355235-79-8 2-(3-benzyloxy-5-methoxyphenyl)-6,7-methylenedioxyquinolin-4(1H)-one 
• 1355235-81-2 2-(3-hydroxy-5-methoxyphenyl)-6,7-methylenedioxy-1H-quinolin-4-one 
• 1355235-82-3 dibenzyl 2-(3-([bis-[(benzyl)oxy]]phosphoryl)oxy-5-methoxyphenyl)-6,7-methylenedioxyquinolin-4-ylphosphate 

Relevant academic research and scientific papers

COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING INFLAMMATORY DISEASES

The present invention is directed to compounds of formula (I), useful in treating and/or preventing inflammatory diseases.

Rational design of inhibitors of the bacterial cell wall synthetic enzyme GlmU using virtual screening and lead-hopping

An aminoquinazoline series targeting the essential bacterial enzyme GlmU (uridyltransferase) were previously reported (Biochem. J. 2012, 446, 405). In this study, we further explored SAR through a combination of traditional medicinal chemistry and structure-based drug design, resulting in a novel scaffold (benzamide) with selectivity against protein kinases. Virtual screening identified fragments that could be fused into the core scaffold, exploiting additional binding interactions and thus improving potency. These efforts resulted in a hybrid compound with target potency increased by a 1000-fold, while maintaining selectivity against selected protein kinases and an improved level of solubility and protein binding. Despite these significant improvements no significant antibacterial activity was yet observed within this class.

Mechanistic studies on regioselective dephosphorylation of phosphate prodrugs during a facile synthesis of antitumor phosphorylated 2-phenyl-6,7-methylenedioxy-1H-quinolin-4-one

Phosphorylation of 2-(3-hydroxy-5-methoxyphenyl)-6,7-methylenedioxy- 1Hquinolin- 4-one (1) afforded diphosphate 2. We found that, upon treatment with methanol under mild conditions, 2 can undergo facile and highly regioselective dephosphorylation to give

SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES

A compound of Formula I is disclosed as follows: or a pharmaceutically acceptable salt, prodrug, solvate, or metabolite thereof, wherein R is hydrogen, P(═O)(OH)2, P(═O)(O(C1-C18)alkylene(C6-C20)aryl)2, P(═O)(OH)(OM), P(═O)(OM)2, P═O(O2M), S(═O)(OH)2, S(═O)(O(C1-C18)alkylene(C6-C20)aryl)2, S(═O)(OH)(OM), S(═O)(OM)2; M is a monovalent or divalent metal ion, or alkylammonium ion; W is (C6-C20)aryl, (C6-C20)heteroaryl, (C1-C18)alkyl(C6-C20)aryl, (C1-C18)alkyl(C6-C20)heteroaryl, hydroxy(C6-C20)aryl, hydroxy(C6-C20)heteroaryl, (C1-C18)alkoxy(C6-C20)aryl, (C1-C18)alkoxy(C6-C20)heteroaryl, (C1-C18)alkylenedioxy(C6-C20)aryl, (C1-C18)alkylenedioxy(C6-C20)heteroaryl, halo(C6-C20)aryl, halo(C6-C20)heteroaryl, (C1-C18)alkylamino(C6-C20)aryl, (C1-C18)alkylamino(C6-C20)heteroaryl, (C1-C18)cycloalkylamino(C6-C20)aryl, or (C1-C18)cycloalkylamino(C6-C20)heteroaryl, and their OR8 substutes; R5 is (C1-C18alkoxy, hydrogen, hydroxyl, O—(C1-C18)alkyl(C6-C20)aryl, halo or OR8, or R5 and R6 are (C1-C18)dioxy provided that R7 is hydrogen; R6 is hydroxyl, O—(C1-C18)alkyl(C6-C20)aryl, halo or ORR, (C1-C18)alkoxy, (C1-C18)alkylamino, or (C1-C18)cycloalkylamino, or R6 and R7 are (C1-C18)dioxy provided that R5 is hydrogen; R7 is hydrogen, halo or OR8, hydroxyl, or O—(C1-C18)alkyl(C6-C20)aryl; and R8 is P(═O)(OH)2, P(═O)(O(C1-C18)alkyl(C6-C20)aryl)2, P(═O)(OH)(OM), or P(═O)(OM)2, P═O(O2M).

PYRROLIDINE OR THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERSAS AS AGONISTS OF G- PROTEIN COUPLED RECEPTOR 43 (GPR43)

The present invention is directed to novel compounds of formula (I) and their use in treating and/or preventing metabolic diseases.

Structural and thermodynamic studies on cation-II interactions in lectin-ligand complexes: High-affinity galectin-3 inhibitors through fine-tuning of an arginine-arene interaction

The high-resolution X-ray crystal structures of the carbohydrate recognition domain of human galectin-3 were solved in complex with N-acetyllactosamine (LacNAc) and the high-affinity inhibitor, methyl 2-acetamido-2-deoxy-4-O-(3-deoxy-3-[4-methoxy-2,3,5,6-tetrafluorobenzamido] -β-D-galactopyranose)-β-D-glucopyranoside, to gain insight into the basis for the affinity-enhancing effect of the 4-methoxy-2,3,5,6- tetrafluorobenzamido moiety. The structures show that the side chain of Arg144 stacks against the aromatic moiety of the inhibitor, an interaction made possible by a reorientation of the side chain relative to that seen in the LacNAc complex. Based on these structures, synthesis of second generation LacNAc derivatives carrying aromatic amides at 3′-C, followed by screening with a novel fluorescence polarization assay, has led to the identification of inhibitors with further enhanced affinity for galectin-3 (Kd ≥ 320 nM). The thermodynamic parameters describing the binding of the galectin-3 C-terminal to selected inhibitors were determined by isothermal titration calorimetry and showed that the affinity enhancements were due to favorable enthalpic contributions. These enhancements could be rationalized by the combined effects of the inhibitor aromatic structure on a cation-Π interaction and of direct interactions between the aromatic substituents and the protein. The results demonstrate that protein-ligand interactions can be significantly enhanced by the fine-tuning of arginine-arene interactions.

A novel class of apical sodium-dependent bile acid transporter inhibitors: The amphiphilic 4-oxo-1-phenyl-1,4-dihydroquinoline derivatives

A series of 4-oxo-1-phenyl-1,4-dihydroquinolines possessing a linker and an ammonio moiety were synthesized and found to inhibit the apical sodium-dependent bile acid transporter (ASBT). The potency of ASBT inhibition varied with the position and length o

PROTEASE INHIBITORS

Disclosed herein is a compound of the formula STR1 known as 2-[N-(N-benzyloxycarbonyl-L-leucinyl)]-2'-[N'-[4-(N,N-dimethylaminomethyl) benzyloxy]carbonyl-L-leucinyl]carbohydrazide; and pharmaceutically acceptable salts, hydrates and solvates thereof.

Long-chain Phenols. Part 16. A Novel Synthesis of Homologous Orsellinic Acids and their Methyl Ethers

By the novel reaction of 3,5-dimethoxyfluorobenzene with n-alkyl-lithium compounds, followed by carbonation, homologous orsellinic acid dimethyl ethers (6-alkyl-2,4-dimethoxybenzoic acids) have been obtained.The reactions proceeded best with the homologues of methyl-lithium.These reactions are considered to occur by way of 3,5-dimethoxybenzyne. 2,4-Dimethoxyfluorobenzene did not form an aryne but gave 3-fluoro-2,6-dimethoxybenzoic acid instead.Decomposition with water of alkyl-lithium reaction mixtures from 3,5-dimethoxyfluorobenzene yielded 5-n-alkylresorcinol dimethyl ethers.Demethylaton of 6-alkyl-2,4-dimethoxybenzoic acids with boron trichloride proceeded partially and selectively to give the 6-alkyl-2-hydroxy-4-methoxybenzoic acids, and completely with aluminium chloride to give the homologous orsellinic acids.Boron tribromide was less effective, but readily gave the 5-alkyl resorcinols from the corresponding dimethyl ethers.